Heart failure & cardiomyopathies
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies
Authors' conclusion
The novel preparation of SC furosemide had similar bioavailability to IV furosemide. Administration via a patch pump was feasible and well tolerated.
Study context
- Population
- Ambulatory patients with heart failure (HF) (pharmacokinetic (PK)/pharmacodynamic (PD) study) and patients hospitalized with HF (patch infusor study)
- Comparison
- Subcutaneous (SC) furosemide vs intravenous (IV) furosemide
- Outcome
- Absolute bioavailability of SC vs IV furosemide (PK/PD study); treatment-emergent adverse events, infusion site pain, device performance and PK measurements (patch infusor study)
Methodological detailstwo studies
- Two studies
Main finding
As reported in the abstract
Absolute bioavailability of SC vs IV furosemide
Absolute bioavailability of SC furosemide vs IV furosemide
112%
Safety
Treatment-emergent adverse events and infusion site discomfort with SC furosemide via patch pump (hospitalized HF)
- Treatment-emergent adverse events
- 0
- Participants reporting no/minor discomfort at infusion site
- 95%
Original publication
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. Eur Heart J Cardiovasc Pharmacother. Published 6 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →